{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:10:04Z","timestamp":1761293404924},"reference-count":61,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2016,4,22]],"date-time":"2016-04-22T00:00:00Z","timestamp":1461283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The carcinoid syndrome represents a set of signs and symptoms associated with neuroendocrine tumors (NETs) that occur primarily when metastases are developed in the liver, resulting in the worsening of quality of life. Serotonin plays a central role in the physiology of carcinoid syndrome by promoting intestinal motility. Somatostatin analogs (SSAs) have widely demonstrated their efficacy as symptomatic relievers of carcinoid syndrome, but this control is ephemeral, being reduced by approximately 50% within the first year. The exact mechanisms of resistance to SSAs are not fully understood, but it is believed that serotonin might be involved. Patients with carcinoid syndrome present with a significant increase in serotonin plasma levels and, consequently, in the soluble urinary metabolite 5-hydroxyindole acetic acid. Telotristat etiprate is a potent inhibitor of tryptophan hydroxylase, a rate-limiting enzyme in the synthesis of serotonin, that has demonstrated in the phase III TELESTAR clinical trial a significant improvement in the control of bowel movements in patients with NETs who have carcinoid syndrome and who have progressed to an SSA. Based on these results, telotristat etiprate has emerged as a potential new option in the treatment algorithm of symptomatic control of functioning NETs. However, some issues need to be clarified, such as the safety profile of the drug outside clinical trials, the benefit in quality of life, and the possible impact on tumor growth, as well as its role within sequencing or combination treatment strategies with pre-existing drugs effective in NET treatment.<\/jats:p>","DOI":"10.1634\/theoncologist.2015-0455","type":"journal-article","created":{"date-parts":[[2016,4,23]],"date-time":"2016-04-23T03:38:31Z","timestamp":1461382711000},"page":"701-707","source":"Crossref","is-referenced-by-count":20,"title":["Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors"],"prefix":"10.1093","volume":"21","author":[{"given":"Javier","family":"Molina-Cerrillo","sequence":"first","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Alonso-Gordoa","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga","family":"Mart\u00ednez-S\u00e1ez","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Hospital Universitario Ram\u00f3n y Cajal, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2016,4,22]]},"reference":[{"key":"2021122309521997300_B1","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.medcli.2014.12.014","article-title":"[Multidisciplinary approach in the diagnosis and therapy of patients with endocrine tumors]","volume":"145","author":"D\u00edez","year":"2015","journal-title":"Med Clin (Barc)"},{"key":"2021122309521997300_B2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309521997300_B3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.7150\/jca.4502","article-title":"Trends of incidence and survival of gastrointestinal neuroendocrine tumors in the United States: A SEER analysis","volume":"3","author":"Tsikitis","year":"2012","journal-title":"J Cancer"},{"key":"2021122309521997300_B4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/annonc\/mdv041","article-title":"Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids","volume":"26","author":"Caplin","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122309521997300_B5","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000382053","article-title":"Clinical syndromes related to gastrointestinal neuroendocrine neoplasms","volume":"44","author":"Boutzios","year":"2015","journal-title":"Front Horm Res"},{"key":"2021122309521997300_B6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1097\/CRD.0b013e3181a6de40","article-title":"Paragangliomas: Etiology, presentation, and management","volume":"17","author":"Joynt","year":"2009","journal-title":"Cardiol Rev"},{"key":"2021122309521997300_B7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0002-8703(54)90152-0","article-title":"Malignant carcinoid of the small intestine with metastases to the liver, valvular disease of the right side of the heart (pulmonary stenosis and tricuspid regurgitation without septal defects), peripheral vasomotor symptoms, bronchoconstriction, and an unusual type of cyanosis; a clinical and pathologic syndrome","volume":"47","author":"Thorson","year":"1954","journal-title":"Am Heart J"},{"key":"2021122309521997300_B8","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1053\/j.gastro.2005.03.038","article-title":"Current status of gastrointestinal carcinoids","volume":"128","author":"Modlin","year":"2005","journal-title":"Gastroenterology"},{"key":"2021122309521997300_B9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"2021122309521997300_B10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ahj.2014.03.018","article-title":"Carcinoid heart disease: Current understanding and future directions","volume":"167","author":"Patel","year":"2014","journal-title":"Am Heart J"},{"issue":"suppl 5","key":"2021122309521997300_B11","doi-asserted-by":"crossref","first-page":"v223","DOI":"10.1093\/annonc\/mdq192","article-title":"Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Oberg","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122309521997300_B12","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1080\/02841860310010547","article-title":"Carcinoid\u2013a comprehensive review","volume":"42","author":"Schnirer","year":"2003","journal-title":"Acta Oncol"},{"key":"2021122309521997300_B13","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1159\/000335136","article-title":"Signaling pathways as specific pharmacologic targets for neuroendocrine tumor therapy: RET, PI3K, MEK, growth factors, and Notch","volume":"97","author":"Carter","year":"2013","journal-title":"Neuroendocrinology"},{"key":"2021122309521997300_B14","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1056\/NEJM199310073291503","article-title":"Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea","volume":"329","author":"Von der Ohe","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122309521997300_B15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11886-006-0019-9","article-title":"Carcinoid heart disease","volume":"8","author":"Connolly","year":"2006","journal-title":"Curr Cardiol Rep"},{"key":"2021122309521997300_B16","first-page":"1061","article-title":"Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: U.S. Department of Health and Human Services interim public health recommendations, November 1997","volume":"46","author":"Centers for Disease Control and Prevention (CDC)","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2021122309521997300_B17","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1021\/ja01154a551","article-title":"The synthesis of 5-hydroxytryptamine","volume":"73","author":"Hamlin","year":"1951","journal-title":"J Am Chem Soc"},{"key":"2021122309521997300_B18","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1126\/science.1078197","article-title":"Synthesis of serotonin by a second tryptophan hydroxylase isoform","volume":"299","author":"Walther","year":"2003","journal-title":"Science"},{"key":"2021122309521997300_B19","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0006-2952(03)00556-2","article-title":"A unique central tryptophan hydroxylase isoform","volume":"66","author":"Walther","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"2021122309521997300_B20","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1007\/s00018-007-7377-3","article-title":"Role of serotonin in the hepato-gastroIntestinal tract: An old molecule for new perspectives","volume":"65","author":"Lesurtel","year":"2008","journal-title":"Cell Mol Life Sci"},{"issue":"suppl 3","key":"2021122309521997300_B21","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/00005344-199000163-00002","article-title":"Origin and metabolism of serotonin","volume":"16","author":"Tyce","year":"1990","journal-title":"J Cardiovasc Pharmacol"},{"issue":"suppl 1","key":"2021122309521997300_B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12325-015-0240-2","article-title":"Regulatory effects of 5-hydroxytryptamine receptors on voiding function","volume":"32","author":"Matsumoto-Miyai","year":"2015","journal-title":"Adv Ther"},{"key":"2021122309521997300_B23","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0091-3057(01)00746-8","article-title":"Molecular, pharmacological and functional diversity of 5-HT receptors","volume":"71","author":"Hoyer","year":"2002","journal-title":"Pharmacol Biochem Behav"},{"key":"2021122309521997300_B24","doi-asserted-by":"crossref","first-page":"18474","DOI":"10.3390\/ijms160818474","article-title":"Functional selectivity and antidepressant activity of serotonin 1A receptor ligands","volume":"16","author":"Chilmonczyk","year":"2015","journal-title":"Int J Mol Sci"},{"key":"2021122309521997300_B25","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1101\/lm.66103","article-title":"Multiple serotonergic mechanisms contributing to sensitization in aplysia: Evidence of diverse serotonin receptor subtypes","volume":"10","author":"Barbas","year":"2003","journal-title":"Learn Mem"},{"key":"2021122309521997300_B26","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0163-7258(01)00169-3","article-title":"Multiplicity of mechanisms of serotonin receptor signal transduction","volume":"92","author":"Raymond","year":"2001","journal-title":"Pharmacol Ther"},{"key":"2021122309521997300_B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/jpet.107.132670","article-title":"Discovery and characterization of novel tryptophan hydroxylase inhibitors that selectively inhibit serotonin synthesis in the gastrointestinal tract","volume":"325","author":"Liu","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"2021122309521997300_B28","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.euroneuro.2008.12.005","article-title":"Spatio-temporal expression of tryptophan hydroxylase isoforms in murine and human brain: Convergent data from Tph2 knockout mice","volume":"19","author":"Gutknecht","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"2021122309521997300_B29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1053\/gast.1996.v111.pm8898642","article-title":"Distinct 5-HT receptors mediate the peristaltic reflex induced by mucosal stimuli in human and guinea pig intestine","volume":"111","author":"Foxx-Orenstein","year":"1996","journal-title":"Gastroenterology"},{"key":"2021122309521997300_B30","first-page":"G778","article-title":"5-HT released by mucosal stimuli initiates peristalsis by activating 5-HT4\/5-HT1p receptors on sensory CGRP neurons","volume":"270","author":"Grider","year":"1996","journal-title":"Am J Physiol"},{"key":"2021122309521997300_B31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-3940(02)00251-3","article-title":"The involvement of 5-HT3 and 5-HT4 receptors in two models of gastrointestinal transit in mice","volume":"326","author":"Pascual","year":"2002","journal-title":"Neurosci Lett"},{"key":"2021122309521997300_B32","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1530\/EJE-14-0354","article-title":"GEP-NETs update: Biotherapy for neuroendocrine tumours","volume":"172","author":"Alonso-Gordoa","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"2021122309521997300_B33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1210\/me.2009-0315","article-title":"Pasireotide and octreotide stimulate distinct patterns of sst2A somatostatin receptor phosphorylation","volume":"24","author":"P\u00f6ll","year":"2010","journal-title":"Mol Endocrinol"},{"key":"2021122309521997300_B34","doi-asserted-by":"crossref","first-page":"21374","DOI":"10.1074\/jbc.M313522200","article-title":"Differential beta-arrestin trafficking and endosomal sorting of somatostatin receptor subtypes","volume":"279","author":"Tulipano","year":"2004","journal-title":"J Biol Chem"},{"key":"2021122309521997300_B35","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jss.2004.03.006","article-title":"Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR","volume":"119","author":"Li","year":"2004","journal-title":"J Surg Res"},{"key":"2021122309521997300_B36","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1523\/JNEUROSCI.16-07-02352.1996","article-title":"Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract","volume":"16","author":"Wade","year":"1996","journal-title":"J Neurosci"},{"key":"2021122309521997300_B37","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2021122309521997300_B38","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122309521997300_B39","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2021122309521997300_B40","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"2021122309521997300_B41","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.cgh.2005.12.008","article-title":"Therapeutic options for gastrointestinal carcinoids","volume":"4","author":"Modlin","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2021122309521997300_B42","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"2021122309521997300_B43","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1677\/erc.1.01200","article-title":"Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma","volume":"13","author":"Butturini","year":"2006","journal-title":"Endocr Relat Cancer"},{"key":"2021122309521997300_B44","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.mce.2007.09.006","article-title":"Pasireotide (SOM230): Development, mechanism of action and potential applications","volume":"286","author":"Schmid","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"2021122309521997300_B45","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1510107","article-title":"High-dose treatment with a long-acting somatostatin analogue in patients with advanced midgut carcinoid tumours","volume":"151","author":"Welin","year":"2004","journal-title":"Eur J Endocrinol"},{"key":"2021122309521997300_B46","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-11-0367","article-title":"Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study","volume":"19","author":"Kvols","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"2021122309521997300_B47","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/01.cco.0000167739.56948.a9","article-title":"Neuroendocrine tumors of the gastrointestinal tract: Recent advances in molecular genetics, diagnosis, and treatment","volume":"17","author":"\u00d6berg","year":"2005","journal-title":"Curr Opin Oncol"},{"key":"2021122309521997300_B48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000055311","article-title":"Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid","volume":"60","author":"Raderer","year":"2001","journal-title":"Oncology"},{"key":"2021122309521997300_B49","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2217\/bmm.11.73","article-title":"\u03b1-Methyl-L-tryptophan: Mechanisms for tracer localization of epileptogenic brain regions","volume":"5","author":"Chugani","year":"2011","journal-title":"Biomarkers Med"},{"key":"2021122309521997300_B50","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2007.12.7431","article-title":"Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: New prognostic factors for malignant well-differentiated endocrine tumors","volume":"26","author":"Asnacios","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122309521997300_B51","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJM196711232772101","article-title":"Inhibition of serotonin synthesis by para-chlorophenylalanine in patients with the carcinoid syndrome","volume":"277","author":"Engelman","year":"1967","journal-title":"N Engl J Med"},{"key":"2021122309521997300_B52","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1136\/gutjnl-2013-304901","article-title":"Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine","volume":"63","author":"Margolis","year":"2014","journal-title":"Gut"},{"key":"2021122309521997300_B53","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1053\/j.gastro.2011.05.005","article-title":"The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome","volume":"141","author":"Brown","year":"2011","journal-title":"Gastroenterology"},{"key":"2021122309521997300_B54","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1016\/j.bmcl.2009.07.005","article-title":"Substituted 3-(4-(1,3,5-triazin-2-yl)-phenyl)-2-aminopropanoic acids as novel tryptophan hydroxylase inhibitors","volume":"19","author":"Jin","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"2021122309521997300_B55","doi-asserted-by":"crossref","first-page":"G455","DOI":"10.1152\/ajpgi.00299.2014","article-title":"Blocking peripheral serotonin synthesis by telotristat etiprate (LX1032\/LX1606) reduces severity of both chemical- and infection-induced intestinal inflammation","volume":"309","author":"Kim","year":"2015","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2021122309521997300_B56","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/ERC-14-0173","article-title":"Telotristat etiprate, a novel serotonin synthesis inhibitor, in patients with carcinoid syndrome and diarrhea not adequately controlled by octreotide","volume":"21","author":"Kulke","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"2021122309521997300_B57","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1210\/jc.2014-2247","article-title":"Telotristat etiprate for carcinoid syndrome: a single-arm, multicenter trial","volume":"100","author":"Pavel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122309521997300_B58","volume-title":"TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)","author":"ClinicalTrials.gov"},{"key":"2021122309521997300_B59","volume-title":"ClinicalTrials.gov. Telotristat etiprate - expanded treatment for patients with carcinoid syndrome symptoms (TELEPATH)"},{"key":"2021122309521997300_B60","volume-title":"ClinicalTrials.gov. Telotristat etiprate for carcinoid syndrome therapy (TELECAST)"},{"key":"2021122309521997300_B61","doi-asserted-by":"crossref","first-page":"5075","DOI":"10.2147\/DDDT.S84177","article-title":"Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues","volume":"9","author":"Wolin","year":"2015","journal-title":"Drug Des Devel Ther"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2015-0455","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2015-0455","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/701\/41874576\/oncolo_21_6_701.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/21\/6\/701\/41874576\/oncolo_21_6_701.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T04:07:17Z","timestamp":1640318837000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/21\/6\/701\/6401407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,22]]},"references-count":61,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016,4,22]]},"published-print":{"date-parts":[[2016,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2015-0455","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,6,1]]},"published":{"date-parts":[[2016,4,22]]}}}